Discovery of New 1,4,6-Trisubstituted-1H-pyrazolo[3,4-b]pyridines with Anti-Tumor Efficacy in Mouse Model of Breast Cancer
Authors:
- Maria GeorgiouMGMaria Georgiou
- Nikolaos LougiakisNLNikolaos Lougiakis
- Roxane TentaRoxane Tenta
- Katerina GiotiKGKaterina Gioti
- Stavroula BaritakiSBStavroula Baritaki
- Lydia-Evangelia GkaraleaLGLydia-Evangelia Gkaralea
- Elisavet DeligianniEDElisavet Deligianni
- Panagiotis MarakosPMPanagiotis Marakos
- Nicole PouliNPNicole Pouli
- Dimitris StellasDSDimitris Stellas
Open Access
- 27 February 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (3) , 787
Abstract
Purine analogues are important therapeutic tools due to their affinity to enzymes or receptors that are involved in critical biological processes. In this study, new 1,4,6-trisubstituted pyrazolo[3,4-b]pyridines were designed and synthesized, and their cytotoxic potential was been studied. The new derivatives were prepared through suitable arylhydrazines, and upon successive conversion first to aminopyrazoles, they were converted then to 1,6-disubstituted pyrazolo[3,4-b]pyridine-4-ones; this served as the starting point for the synthesis of the target compounds. The cytotoxic activity of the derivatives was evaluated against several human and murine cancer cell lines. Substantial structure activity relationships (SARs) could be extracted, mainly concerning the 4-alkylaminoethyl ethers, which showed potent in vitro antiproliferative activity in the low μM level (0.75–4.15 μΜ) without affecting the proliferation of normal cells. The most potent analogues underwent in vivo evaluation and were found to inhibit tumor growth in vivo in an orthotopic breast cancer mouse model. The novel compounds exhibited no systemic toxicity; they affected only the implanted tumors and did not interfere with the immune system of the animals. Our results revealed a very potent novel compound which could be an ideal lead for the discovery of promising anti-tumor agents, and could also be further explored for combination treatments with immunotherapeutic drugs.Keywords
This publication has 30 references indexed in Scilit:
- Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitorsBioorganic Chemistry, 2016
- N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf InhibitorsACS Medicinal Chemistry Letters, 2015
- Therapeutic Effects of an Anti-Myc Drug on Mouse Pancreatic CancerJNCI: Journal of the National Cancer Institute, 2014
- Overall Synthesis of GSK356278: Quick Delivery of a PDE4 Inhibitor Using a Fit-for-Purpose ApproachOrganic Process Research & Development, 2010
- ChemInform Abstract: Synthesis of Some Novel Pyrazolo[3,4-b]pyridine and Pyrazolo[3,4-d]pyrimidine Derivatives Bearing 5,6-Diphenyl-1,2,4-triazine Moiety as Potential Antimicrobial Agents.ChemInform, 2010
- Synthesis of some novel pyrazolo[3,4-b]pyridine and pyrazolo[3,4-d]pyrimidine derivatives bearing 5,6-diphenyl-1,2,4-triazine moiety as potential antimicrobial agentsEuropean Journal of Medicinal Chemistry, 2009
- Synthesis and 3D QSAR of New Pyrazolo[3,4-b]pyridines: Potent and Selective Inhibitors of A1Adenosine ReceptorsJournal of Medicinal Chemistry, 2005
- Reaction of 5‐amino‐1‐aryl‐3‐methylpyrazoles with benzylidene derivatives of meldrum's acid: Synthesis and characterization of pyrazolo[3,4‐b]pyridinonesJournal of Heterocyclic Chemistry, 1998
- Synthesis and adenosine receptor affinity of a series of pyrazolo[3,4-d]pyrimidine analogs of 1-methylisoguanosineJournal of Medicinal Chemistry, 1991
- Pyrazolo[3,4-b]pyridines: Syntheses, reactions, and nuclear magnetic resonance spectraCanadian Journal of Chemistry, 1988